These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 22792467)

  • 1. Effects of statins on cardiorenal syndrome.
    Yagi S; Aihara K; Ikeda Y; Akaike M; Sata M; Matsumoto T
    Int J Vasc Med; 2012; 2012():162545. PubMed ID: 22792467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy.
    Danesh FR; Kanwar YS
    FASEB J; 2004 May; 18(7):805-15. PubMed ID: 15117885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statins: a new insight into their mechanisms of action and consequent pleiotropic effects.
    Jasińska M; Owczarek J; Orszulak-Michalak D
    Pharmacol Rep; 2007; 59(5):483-99. PubMed ID: 18048949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statins: a treatment option for chronic heart failure?
    von Haehling S; Okonko DO; Anker SD
    Heart Fail Monit; 2004; 4(3):90-7. PubMed ID: 15772704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statins: potential new indications in inflammatory conditions.
    Endres M
    Atheroscler Suppl; 2006 Apr; 7(1):31-5. PubMed ID: 16503422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pleiotropic effects of statins: evidence for benefits beyond LDL-cholesterol lowering.
    Marzilli M
    Am J Cardiovasc Drugs; 2010; 10 Suppl 1():3-9. PubMed ID: 21391728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin converting enzyme (ACE) and HydroxyMethylGlutaryl-CoA (HMG-CoA) reductase inhibitors in the forefront of pharmacology of endothelium.
    Chłopicki S; Gryglewski RJ
    Pharmacol Rep; 2005; 57 Suppl():86-96. PubMed ID: 16415489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pleiotropic effects of HMG-CoA reductase inhibitors.
    Bocan TM
    Curr Opin Investig Drugs; 2002 Sep; 3(9):1312-7. PubMed ID: 12498006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Range of adiposity and cardiorenal syndrome.
    Pazos F
    World J Diabetes; 2020 Aug; 11(8):322-350. PubMed ID: 32864046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy.
    Woodman RJ; Chew GT; Watts GF
    Drugs; 2005; 65(1):31-74. PubMed ID: 15610050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent developments in the effects of nitric oxide-donating statins on cardiovascular disease through regulation of tetrahydrobiopterin and nitric oxide.
    Ma S; Ma CC
    Vascul Pharmacol; 2014 Nov; 63(2):63-70. PubMed ID: 25139660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Should statins be part of the treatment of heart failure?].
    Trochu JN
    Ann Cardiol Angeiol (Paris); 2004 Jul; 53(4):209-16. PubMed ID: 15369317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins?
    Balakumar P; Kathuria S; Taneja G; Kalra S; Mahadevan N
    J Mol Cell Cardiol; 2012 Jan; 52(1):83-92. PubMed ID: 21968328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis.
    Ni W; Egashira K; Kataoka C; Kitamoto S; Koyanagi M; Inoue S; Takeshita A
    Circ Res; 2001 Aug; 89(5):415-21. PubMed ID: 11532902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of Endothelial Function by HMG-CoA Reductase Inhibitors.
    Wassmann S; Nickenig G
    Drug News Perspect; 2002 Mar; 15(2):85-92. PubMed ID: 12677213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of statins on endothelium, inflammation and cardioprotection.
    Elrod JW; Lefer DJ
    Drug News Perspect; 2005 May; 18(4):229-36. PubMed ID: 16034478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins.
    Lahera V; Goicoechea M; de Vinuesa SG; Miana M; de las Heras N; Cachofeiro V; Luño J
    Curr Med Chem; 2007; 14(2):243-8. PubMed ID: 17266583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
    Rosenson RS
    Am J Cardiovasc Drugs; 2001; 1(6):411-20. PubMed ID: 14728000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HMG-CoA reductase inhibitors in chronic heart failure: potential mechanisms of benefit and risk.
    Laufs U; Custodis F; Böhm M
    Drugs; 2006; 66(2):145-54. PubMed ID: 16451090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid oxidative stress and the anti-inflammatory properties of statins and ACE inhibitors.
    Cattaneo D; Remuzzi G
    J Ren Nutr; 2005 Jan; 15(1):71-6. PubMed ID: 15648011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.